ライフサイエンスコーパス: FNA

1 FNA biopsies provide a diagnostic to rapidly phenotype t

2 FNA has had greatest efficacy in confirming celiac axis

3 FNA is a common method of diagnosis for pancreatic cance

4 FNA material was separately cultured for a short time in

5 FNA samples from melanoma xenografts showed comparable e

6 FNA samples from patients with metastatic melanoma succe

7 FNA samples were representative of the tumor as a whole

8 FNA samples yielded greater numbers of viable cells when

9 FNA sequencing is feasible and subsets of patients may h

10 FNA sequencing opens the door to clinical trials in whic

11 FNA treatment decreased the biomass-specific N2O product

12 FNA-derived cultures were evaluated for anchorage-indepe

13 FNAs mainly include DNAzymes, G-quadruplexes, and mismat

14 FNAs that are expanded from a wide range of clinical bre

15 Of 115 FNA procedures, 93 were completed for the initial evalua

16 of the 470 patients underwent a total of 115 FNA procedures, which were assessed by more than 70 diff

17 models of metastatic melanoma, as well as 12 FNA samples from patients with metastatic melanoma.

18 ese cutoffs in two independent datasets: 123 FNA samples and 177 tissue samples (ie, resected or core

19 49 true-negative (TN, 18%), and 34 FN (13%) FNA results.

20 nd 8 tumor cell lines were generated from 18 FNA (12 patients).

21 For the 22 FNAs done for recurrent disease, only nine (41%) were cl

22 Seven of the 24 FNAs with immunophenotyping (29%) were correlated with s

23 Only one (2%) of 43 FNA diagnoses, based on morphology alone, was correlated

24 We collected a minimum of 6 FNA samples from each of 250 patients during EUS.

25 e paired comparisons, only eight (12%) of 67 FNA diagnoses were correlated with the subsequent excisi

26 Of the 93 FNA attempts at initial diagnosis, only 27 (29%) were gi

27 Sixty-seven (72%) of the 93 FNAs performed for the evaluation of initial disease had

28 eatment strategy based on free nitrous acid (FNA or HNO2) to enhance methane production from WAS.

29 ) that was established by free nitrous acid (FNA)-based sludge treatment was not higher but much lowe

30 ion sensors using functional nucleic acids (FNAs) and nanomaterials.

31 Functional nucleic acids (FNAs) are a class of biomolecules that can exhibit eithe

32 ues or the use of instrument-based analysis, FNA-based biosensors are capable of entering cells witho

33 d forty-one (341) patients underwent EUS and FNA of a pancreatic cystic lesion; 112 of these patients

34 g peripheral blood, bulk resected tumor, and FNA were analyzed from 13 mesothelioma patients.

35 osis of malignancy in fine-needle aspirates (FNA) and biliary brushing specimens from patients with p

36 lls within samples of fine-needle aspirates (FNA) can be propagated in culture.

37 ymphocytes (TIL) from fine needle aspirates (FNA) of tumors potentially allows a dynamic evaluation o

38 time evaluation with fine-needle aspiration (FNA) and combinations of chemical-shift MRI, noncontrast

39 ens obtained through fine-needle aspiration (FNA) and excisional biopsy were tested for M. tuberculos

40 ytologic features on fine needle aspiration (FNA) biopsy require thyroidectomy because of a 20% to 30

41 sis was performed on fine needle aspiration (FNA) biopsy samples from four murine xenograft models of

42 f thyroid nodules on fine needle aspiration (FNA) cytology samples has given clinicians a new level o

43 -guided percutaneous fine-needle aspiration (FNA) has become the procedure of choice for biopsies of

44 Fine-needle aspiration (FNA) is increasing in popularity as a means of diagnosin

45 ographic (US)-guided fine-needle aspiration (FNA) of axillary lymph nodes for preoperative staging of

46 CT-guided fine-needle aspiration (FNA) of lung lesions is subject to sampling errors.

47 diagnostics included fine needle aspiration (FNA) of suspicious lesions and mini-laparoscopy to estab

48 Fine-needle aspiration (FNA) of thyroid nodules has become the primary diagnosti

49 Fine-needle aspiration (FNA) or stereotactic core biopsy was used to diagnose 19

50 plified RNAs from 63 fine needle aspiration (FNA) samples from 37 s.c. melanoma metastases from 25 pa

51 Data from 195 fine-needle aspiration (FNA) samples were used to define mRNA cutoff values that

52 ng of thyroid nodule fine-needle aspiration (FNA) specimens has been proposed as an adjunct to the cy

53 chieved at EUS using fine-needle aspiration (FNA) to obtain cytology from suspect Ns.

54 imaging and guided, fine-needle aspiration (FNA).

55 ould be studied with fine-needle aspiration (FNA).

56 d effectively by EUS-fine needle aspiration (FNA).

57 ltrasonography (EUS) fine-needle aspiration (FNA).

58 Pretreatment of WAS for 24 h at FNA concentrations up to 2.13 mg N/L substantially enhan

59 Anatomy- and metabolism-based FNA guidance using information provided by both (18)F-FD

60 These results indicate that [3H]beta-FNA binds covalently to Lys233.

61 Since [3H]beta-FNA is a rigid molecule, the information will be very us

62 rated that [3H]beta-funaltrexamine ([3H]beta-FNA) labeled the rat mu opioid receptor expressed in Chi

63 tely eliminated covalent binding of [3H]beta-FNA, although these mutants bound beta-FNA with high aff

64 ry cells with high specificity, and [3H]beta-FNA-labeled receptors migrated as one broad band with a

65 [3H]beta-FNA-labeled receptors were solubilized and purified to a

66 did not affect covalent binding of [3H]beta-FNA.

67 involved in the covalent binding of [3H]beta-FNA.

68 receptor binding decreased 24 hr after beta-FNA injection and returned to control levels 11 d after

69 In pretrained animals, beta-FNA significantly impaired spatial memory retrieval and

70 re, pretreatment with the mu antagonist beta-FNA (1.00-2.00 microg) attenuated antinociception induce

71 Behaviorally, beta-FNA prevented morphine-induced loss of righting and Stra

72 ]beta-FNA, although these mutants bound beta-FNA with high affinity.

73 er degree by NTI, and was unaffected by beta-FNA.

74 ceptor antagonist, beta-funaltrexamine (beta-FNA) also results in opioid analgesia.

75 eceptor antagonist beta-funaltrexamine (beta-FNA) into area CA3.

76 ceptor antagonist, beta-funaltrexamine (beta-FNA), prior to parturition interfered with the establish

77 ceptor antagonist, beta-funaltrexamine (beta-FNA), prior to systemic morphine injection.

78 ceptor antagonist, beta-funaltrexamine (beta-FNA), was unilaterally infused into the PAG adjacent to

79 either naltrexone, beta-funaltrexamine (beta-FNA, mu), nor-binaltorphamine (NBNI, kappa) or naltrindo

80 re pretreated with beta-funaltrexamine (beta-FNA; 15 mg/kg s.c), an irreversible mu-opioid receptor a

81 NTB, beta-FNA, and nor-BNI were unable to block the cardioprotecti

82 The amino acid residue of beta-FNA covalent incorporation was then determined by site-d

83 Injections of beta-FNA into the CA3 region, but not into the ventricles, ca

84 ectivity, whereas the agonist effect of beta-FNA is clearly kappa opioid receptor (KOR) mediated.

85 Infusion of beta-FNA near specific medial thalamic nuclei attenuated morp

86 In the CPu of beta-FNA treated rats, morphine-induced c-Fos and JunB were a

87 ith the prototypic fumaroylamino opioid beta-FNA (1a) shows that they have similar MOR irreversible a

88 Ultra-low-dose NTX, nor-BNI or beta-FNA selectively antagonizes high-efficacy excitatory (hy

89 of these in fine needle aspiration biopsies (FNA).

90 ave developed a fine needle aspirate biopsy (FNA) platform to perform immune profiling on thoracic ma

91 iopsy and 15 of 195 (7.7%) were diagnosed by FNA or stereotactic core biopsy.

92 DNA from both simulated FNAs and clinical FNAs was sequenced.

93 ith score 1 or 2 registration quality for CT FNA and PET/CT/CT images, including 179 TP (67%), 5 fals

94 T images performed for the FNA procedure (CT FNA) with corresponding slices of the PET/CT study.

95 rasound and fine-needle aspiration cytology (FNA).

96 ethods based on the combination of different FNAs and nanomaterials are discussed.

97 EBUS-FNA was more sensitive than TBNA, detecting 29 (69%) vs

98 The combination of EUS-FNA and EBUS-FNA (EUS plus EBUS) had higher estimated sensitivity (93

99 In particular, we aimed to compare EBUS-FNA with TBNA.

100 TBNA, EBUS-FNA, and EUS-FNA performed sequentially as a single comb

101 These findings suggest that EBUS-FNA has higher sensitivity than TBNA and that EUS plus E

102 EUS FNA is more accurate for nodal staging and impacts on th

103 EUS FNA resulting in a higher/worse stage than CT (41 patien

104 EUS FNA should be included in the preoperative staging algor

105 EUS FNA was more sensitive (83% vs. 29%; P < 0.001) than CT

106 formance characteristics of CT, EUS, and EUS FNA for preoperative nodal staging of esophageal carcino

107 d tumor stage determined by CT, EUS, and EUS FNA were associated with treatment decisions (P < 0.05).

108 rospectively evaluated with CT, EUS, and EUS FNA.

109 le of EUS-guided fine-needle aspiration (EUS FNA) in this setting is unclear.

110 EUS-FNA accurately and safely evaluates solid peri-intestina

111 EUS-FNA as a first test (after CT) has high diagnostic yield

112 EUS-FNA established tissue diagnosis in 70% of cases.

113 EUS-FNA is able to detect occult metastasis to the CLNs and

114 EUS-FNA sensitivity, specificity, and accuracy was 92%, 93%,

115 EUS-FNA was performed in 457 patients with 554 lesions.

116 EUS-FNA was significantly better than CT at detecting distan

117 EUS-FNA with histology of the specimens is a sensitive and a

118 EUS-FNA, CT, and positron emission tomography detected metas

119 a more indolent clinical course; and (3) EUS-FNA may be useful for the diagnosis and management of GI

120 TBNA, EBUS-FNA, and EUS-FNA performed sequentially as a single combined procedur

121 trasound-guided, fine-needle aspiration (EUS-FNA) biopsy and were resected.

122 ltrasound-guided fine-needle aspiration (EUS-FNA) for diagnosis of metastases to the pancreas.

123 ultrasound with fine needle aspiration (EUS-FNA) remain the preferred methods.

124 ltrasound-guided fine needle aspiration (EUS-FNA) was allowed as an alternative procedure.

125 ltrasound-guided fine needle aspiration (EUS-FNA) was evaluated as a single test for the diagnosis an

126 ltrasound-guided fine-needle aspiration [EUS-FNA]) is capable of sampling lymph nodes for PCR analysi

127 hy-guided fine-needle aspiration biopsy (EUS-FNA) permits cytological confirmation of EUS findings.

128 firmed in 32 (1.6%) cases, 30 of them by EUS-FNA, and 2 by surgery.

129 -guided fine needle aspiration cytology (EUS-FNA), and the newest emerging application is EUS-guided

130 Minimally invasive EUS-FNA with RT-PCR is capable of detecting expression of ca

131 The diagnostic yields of EUS-FNA and CT for detection of metastases to the CLNs were

132 The combination of EUS-FNA and EBUS-FNA (EUS plus EBUS) had higher estimated se

133 The performance of EUS-FNA for diagnosis of pancreatic metastases was analyzed.

134 The sensitivity of EUS-FNA for pancreatic adenocarcinoma is excellent (more tha

135 A multicenter prospective evaluation of EUS-FNA for primary diagnosis, staging, and/or follow-up pur

136 The accuracy of EUS-FNA in patients with previously failed biopsy procedures

137 ative predictive values, and accuracy of EUS-FNA with histology analysis of the specimens for diagnos

138 diagnosis was based on a combination of EUS-FNA, surgery and follow-up of minimum 6 months in negati

139 for EUS, but most of the emphasis is on EUS-FNA and EUS-guided interventions.

140 nd fluorescence in-situ hybridization on EUS-FNA samples may increase the yield and prove to be bette

141 cases with resectable tumor on CT scan, EUS-FNA avoided thoracotomy in 14% of cases.

142 ile FDG-PET/CT may be more accurate than EUS-FNA and CT scan for predicting nodal status and complete

143 hat FDG-PET/CT may be more accurate than EUS-FNA and CT scan for predicting nodal status and complete

144 37 patients underwent EUS-FNA for probable pancreas metastases.

145 revious extrapancreatic cancer underwent EUS-FNA from January/1997 to December/2010.

146 ients from the EBUS-TBNA group underwent EUS-FNA.

147 When EUS-FNA was compared with EUS size criteria in lymph node ev

148 ediastinal lymph nodes were sampled with EUS-FNA in patients with NSCLC and negative control subjects

149 oregional staging is best performed with EUS-FNA, with CT scan of the thorax and abdomen and FDG-PET,

150 red for cases with true-positive (TP) and FN FNA results.

151 For FNA specimens, the sensitivity was 17.1%, and the specif

152 to the limited quantity of DNA derived from FNA specimens and tumor heterogeneity.

153 who underwent (18)F-FDG PET/CT and CT-guided FNA within an interval of less than 30 d were retrospect

154 e and thus improve the accuracy of CT-guided FNA.

155 Endoscopic ultrasonography-guided FNA biopsy may play a valuable role in the evaluation of

156 results on endoscopic ultrasonography-guided FNA biopsy were positive in 57 patients, negative in 37,

157 eatitis on endoscopic ultrasonography-guided FNA biopsy.

158 underwent endoscopic ultrasonography-guided FNA biopsy.

159 ristics of endoscopic ultrasonography-guided FNA for diagnosing pancreatic masses were determined.

160 stochemical analysis using ultrasound-guided FNA biopsy, guiding the clinician to nodal excision rath

161 US-guided FNA did not result in any intra- or postprocedural compl

162 ical intervention after diagnostic US-guided FNA findings, results of surgical-pathologic analysis he

163 Sensitivity of US-guided FNA for predicting positive results at ALND or SNB was 7

164 nodules (n = 5349) that underwent US-guided FNA in 2004-2012 were identified; 393 were single nodule

165 US-guided FNA in the most suspicious node at US, or the largest no

166 Sensitivity of US-guided FNA increased with primary tumor size.

167 The diagnostic accuracy of US-guided FNA is similar to that of core needle biopsy, and there

168 US-guided FNA of axillary lymph nodes in patients with newly diagn

169 ars]) who underwent 52 consecutive US-guided FNA procedures from 2004 to 2009 were reviewed.

170 US-guided FNA results in 74 patients with breast cancer (75 axilla

171 compared with US and preoperative US-guided FNA results.

172 ositive predictive value of US and US-guided FNA were calculated.

173 tion on the basis of findings from US-guided FNA.

174 We hypothesize that free nitrous acid (HNO2, FNA) may assist in the (partial) disruption of extracell

175 ave been used as in vivo biosensors, and how FNAs can be coupled to transduction systems and delivere

176 In FNAs obtained from 17 patients with unresectable disease

177 In FNAs, genetic alterations were detected in 19/44 maligna

178 methane production increased with increased FNA concentration used in the pretreatment step.

179 e substrates, which increased with increased FNA dose, while the slowly biodegradable substrates rema

180 f surgery in a patient with an indeterminate FNA biopsy.

181 of malignancy in cytologically indeterminate FNAs.

182 a possible diagnostic tool for indeterminate FNAs, and as a determinant for planning initial clinical

183 Model-based analysis indicated FNA pretreatment improved both hydrolysis rate and metha

184 In selected instances, FNA is superior to core-needle or open biopsy in terms o

185 l thyroid cancer (24 papillary, 11 malignant FNA, 5 oncocytic/Hurthle cell, 2 medullary, 1 follicular

186 he feasibility of TIL expansion from minimal FNA material and localization of vaccine-specific T cell

187 y ranged from $746 (NP-59) to $1745 (MRI +/- FNA).

188 2839 (CT0) and 759 (NP-59) and 1982 (MRI +/- FNA) for cost and diagnostic accuracy, respectively.

189 a novel approach termed flexible nanoarray (FNA) in which the interaction between the two internally

190 A negative FNA does not reliably rule out infection.

191 osed with repeat FNA following nondiagnostic FNA results (two of 336, 0.6%); therefore, clinical and

192 ; 393 were single nodules with nondiagnostic FNA results but adequate cytologic, surgical, or US foll

193 analysis improved the diagnostic accuracy of FNA biopsy in 35 of 38 indeterminate or suspicious resul

194 e used to improve the diagnostic accuracy of FNA biopsy.

195 urance criteria to determine the accuracy of FNA procedures to sample tumor tissue.

196 piration in lung lesions and the accuracy of FNA results.

197 hors also discuss some of the limitations of FNA and how to optimize the procurement and utilization

198 This review offers a summary of FNA- and nanomaterial-based metal ion detection methods.

199 Molecular testing of FNA specimens may help to avoid diagnostic thyroidectomy

200 The roles of FNAs and nanomaterials are introduced first.

201 eview is to examine how molecular testing of FNAs could be used to guide surgical decision-making.

202 Here, we review the types of FNAs that have been used as in vivo biosensors, and how

203 ative frequency of indeterminate cytology on FNA could necessitate surgery in a large number of patie

204 ed on every other specimen (from every other FNA pass); patients were randomly assigned to the first

205 Overall, FNA for lymphoma diagnosis is not helpful, not cost effe

206 otyping was completed on 24 of the 67 paired FNAs.

207 patients with enlarging or symptomatic post-FNA pneumothoraces treated with a small-caliber catheter

208 Moreover, preoperative FNA sequencing has the potential to influence the timing

209 ortion of thyroid carcinomas in preoperative FNAs in our cohort and thus is not sufficient to rule ou

210 ic TIL could be expanded from prevaccination FNA.

211 ollow-up may be more appropriate than repeat FNA following nondiagnostic biopsy results.

212 .3%) were subsequently diagnosed with repeat FNA (n = 2, 0.5%) or surgical pathologic examination (n

213 few malignancies were diagnosed with repeat FNA following nondiagnostic FNA results (two of 336, 0.6

214 In a direct comparison of the same FNA also tested by an RNA-based gene expression classifi

215 Serial FNA of the same lesions were performed in five HLA-A*020

216 concordance was determined between simulated FNAs and that of the resected specimen.

217 DNA from both simulated FNAs and clinical FNAs was sequenced.

218 Comparison of simulated FNAs and matched tumor tissue exhibited a concordance fr

219 survival, thyroid cancer-specific survival, FNA, and histopathology were collected until January 201

220 Microbial analysis revealed that FNA treatment decreased the microbial community diversit

221 n investigation of the mechanism showed that FNA treatment caused a shift of the stimulation threshol

222 The FNA design allowed reversible experiments in which the m

223 The FNA tether was synthesized with nonnucleotide phosphoram

224 used to register CT images performed for the FNA procedure (CT FNA) with corresponding slices of the

225 This excluded PBMC contamination of the FNA material.

226 these experiments, the thiolated end of the FNA tether was covalently immobilized on the AFM substra

227 The other end of the FNA tether was functionalized with biotin to form a nonc

228 This suggests that the FNA technique is capable of analyzing multiple intermole

229 by nontethered peptides, suggesting that the FNA tether has the necessary flexibility to enable assem

230 as been used along with the Bethesda Thyroid FNA Classification System to offer preoperative guidance

231 uary 1994 through December 2000, 709 thyroid FNAs were performed at a single institution.

232 TCGA-reported genomic alterations in thyroid FNAs.

233 Thyroid nodules whose FNA is diagnosed as highly suspicious for malignancy sho

234 h diverse pathologies who underwent EUS with FNA, despite limited tissue sampling for FISH analysis.

235 Information yielded with FNA cytology plays an integral role in clinical decision

236 sterol (NP-59) scintigraphy, with or without FNA, in a hypothetical cohort of 1000 patients with inci

237 13 mg HNO2-N/L) being six times that without FNA pretreatment (0.025 mg COD/mg VS, at 0 mg HNO2-N/L).